Alamar Biosciences, Inc.

What they do

Alamar markets an integrated proteomics platform—ARGO HT instruments, NULISA consumables, and related software—to measure low-abundance protein biomarkers in blood. Its customers include academic institutions, biopharma companies, CROs, and service labs, with direct sales in North America, Europe, and China and distributors covering other regions. For Q2 2026, 52% of sales revenue came from academic institutions, 42% from biopharma, and 6% from distributors; 69% of sales were in the Americas, 22% in EMEA, and 9% in APAC. The platform is currently sold for research use only.

Revenue drivers

• Consumables (NULISA panels) — Largest and fastest-growing segment; Q2 2026 revenue $15.5M, up 147% year-over-year, driven by demand for multiplex panels; high-margin and a key part of the pull-through model.
• Instruments (ARGO HT System) — Q2 2026 revenue $7.8M, up 35% year-over-year; growth from new instrument placements; installed base exceeded 100 instruments with average annual pull-through >$400,000 in 2025.
• Services and other — Includes services and other revenue; Q2 2026 revenue $6.2M, up 49% year-over-year from $4.1M in Q2 2025.

Recent performance

Q2 2026 total revenue was $29.4M, an 82% increase from $16.2M in Q2 2025. Consumable revenue grew 147%, instrument revenue grew 35%, and services and other grew 49% year-over-year. Gross margin improved to 60% from 53%, due to manufacturing efficiencies and mix shift to consumables. Operating expenses rose 89% to $31.2M on investments in headcount, infrastructure, R&D, and public company costs; operating loss widened to $13.5M from $7.9M, including $3.3M of stock-based compensation. Net loss was $13.2M versus $7.0M in the prior-year period.

Strategy

Management focuses on expanding the assay menu—launching the NULISAseq Immune 340 Panel and the eMTBR-tau assay in Q2 2026—and on growing the installed base of ARGO HT instruments to drive recurring consumable pull-through. They are developing the ARGO HT/DX instrument for FDA submission in 2027, targeting diagnostics. The company is also building collaborations in neurodegenerative disease, including with the Alzheimer's Disease Data Initiative and Gates Ventures, and investing in R&D capabilities and headcount. Full-year 2026 revenue guidance of $116M–$120M implies ~59% growth at the midpoint over 2025.

Risks

• Rapidly growing operating losses — Operating loss nearly doubled year-over-year to $13.5M in Q2 2026, driven by a 89% increase in operating expenses, and net loss widened to $13.2M.
• Research-use-only limitation — Products are sold for research use only; the company has no FDA clearance yet, and the ARGO HT/DX instrument is not expected to be submitted to the FDA until 2027.
• Customer concentration and geographic mix — Revenue relies heavily on academic institutions (52% of Q2 2026 sales) and the Americas region (69%), making the company sensitive to academic funding and regional demand shifts.
• Future capital needs — Despite $256.3M in cash and investments, ongoing losses and planned R&D investment may require additional capital; no assurance of future funding is provided.

Outlook

Management expects full-year 2026 revenue of $116M to $120M, representing growth of about 59% at the midpoint versus 2025. They cite recent product launches (eMTBR-tau, Immune 340 Panel) and strategic partnerships as drivers of continued momentum. The company plans to submit the ARGO HT/DX instrument for FDA marketing authorization in 2027.